Last reviewed · How we verify
GSK3888550A RSV Maternal vaccine formulation 1
GSK3888550A RSV Maternal vaccine formulation 1 is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 1 development.
At a glance
| Generic name | GSK3888550A RSV Maternal vaccine formulation 1 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Injection site pain
- Headache
- Fatigue
- Gastrointestinal disorder
- Injection site inflammation
- Nasopharyngitis
- Injection site swelling
- Back pain
- Pain in extremity
- Oropharyngeal pain
- Pyrexia
- Injection site bruising
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK3888550A RSV Maternal vaccine formulation 1 CI brief — competitive landscape report
- GSK3888550A RSV Maternal vaccine formulation 1 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK3888550A RSV Maternal vaccine formulation 1
What is GSK3888550A RSV Maternal vaccine formulation 1?
GSK3888550A RSV Maternal vaccine formulation 1 is a Biologic drug developed by GlaxoSmithKline.
Who makes GSK3888550A RSV Maternal vaccine formulation 1?
GSK3888550A RSV Maternal vaccine formulation 1 is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is GSK3888550A RSV Maternal vaccine formulation 1 in?
GSK3888550A RSV Maternal vaccine formulation 1 is in Phase 1.
What are the side effects of GSK3888550A RSV Maternal vaccine formulation 1?
Common side effects of GSK3888550A RSV Maternal vaccine formulation 1 include Injection site pain, Headache, Fatigue, Gastrointestinal disorder, Injection site inflammation, Nasopharyngitis.